ClinicalTrials.gg

Iron Deficiencies clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 386 studies for Iron Deficiencies across more than 10 countries. 78 are recruiting or about to start. 182 of them are mainly about Iron Deficiencies (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its narrower condition Anemia, Iron-Deficiency too: 875 studies, 152 open.

Status

Completed
239
Recruiting
53
Status unknown
34
Not yet recruiting
22
Terminated
16
Active, not recruiting
12

Phase

Phase 4
60
Phase 3
47
Phase 2
25
Phase 1
12
Early Phase 1
4

Where

United States
82
Switzerland
44
United Kingdom
22
Germany
21
Canada
18
China
17

Who develops what

Add Iron Deficiencies to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 3 programs from 2 companies, 1 with this as their studies’ main aim; 1 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
ferric maltolRecent, limited
Evidence
  • NCT07308769 · pharmanutra s p a · Phase 4 · live · comparator · “Ferric Maltol (Feraccru®)” · registered Dec 2025
Shield Therapeutics88% of its industry studiesUS: Shield Therapeutics (FDA 2019)EU: Norgine (EMA 2016)11 study
iron sucroseEarlier only
Evidence
  • NCT02130063 · Pharmacosmos A/S · Phase 3 · comparator · “iron sucrose (Venofer®)” · registered Apr 2014
  • NCT01052779 · Azurity Pharmaceuticals · Phase 2 · comparator · “Iron Sucrose” · registered Jan 2010
  • NCT00810030 · CSL Limited · Phase 3 · comparator · “Iron Sucrose” · registered Dec 2008
Daiichi Sankyo50% of its industry studiesUS: off-patent, 3 generics marketed00 studies
ferrous sulfateEarlier onlyPhase 4 trial recorded
Evidence
  • NCT01017614 · Pharmacosmos A/S · Phase 3 · comparator · “Iron Sulphate” · registered Nov 2009
  • NCT00224055 · AbbVie · Phase 4 · comparator · “Ferrous sulfate tablets” · registered Sep 2005
  • NCT00224042 · AbbVie · Phase 4 · comparator · “Ferrous sulfate tablets” · registered Sep 2005
Daiichi Sankyo33% of its industry studies00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 3 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Apr 2027 est.iron isomaltoside 1000 · Pharmacosmos A/S · Phase 3 main aimNCT05179226 Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia — primary endpoint: Incidence of subjects with a Hb increase of ≥1 g/dL (NDD-CKD) or 2 g/dL (intolerant or unresponsive to oral iron). Measurement by bloodsample. · 200 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Iron Deficiencies studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

34studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 53 Iron Deficiencies studies recruiting now, 23 (43%) set no upper age limit and 26 (49%) stop at 75 or younger. 14 (26%) take children under 18. 16 (30%) are for women only and 0 (0%) for men only; 15 (28%) take healthy volunteers.

Recruiting studies that take each age, of 53
AgeWomenMen
108 (15%)7 (13%)
1841 (77%)26 (49%)
3039 (74%)23 (43%)
4036 (68%)23 (43%)
5028 (53%)23 (43%)
6527 (51%)23 (43%)
7527 (51%)23 (43%)
8527 (51%)23 (43%)

Across all 386 studies, recruiting or not: 59% stop at 75 or younger and 57% at 65; 30% take children; 34% are for women only and 1% for men only; 43% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Iron Deficiencies studies take

Of 26 phase 4 interventional studies under Iron Deficiencies, half reached primary completion within 39 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 333 mo19–60 · 16 studies——
Phase 439 mo20–64 · 26 studies——
Interventional, no phase10 mo5–26 · 89 studies—9 mo5–26 · 77 studies
Observational30 mo13–57 · 24 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 386. Browse all 386 → or search them.